View Older Stories View More Recent Stories
-
Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
-
HSBC Upgrades Moderna (MRNA) to Hold
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
-
Moderna (MRNA) Receives European Commission Approval for RSV Vaccine mRESVIA(R)
-
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
-
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
-
Moderna (MRNA) Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
-
Moderna to Host Investor Event - R&D Day and Business Updates
-
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
-
Moderna stock: What could trigger a turnaround over the next 3-6 months?
-
Moderna and Coursera Launch Free Course on mRNA Technology
-
Deutsche Bank Upgrades Moderna (MRNA) to Hold, 'a more troublesome Winter’s Tale, but up to Hold'
-
Midday movers: Apple, Nvidia, Intel, Coinbase and Moderna fall
-
RBC Capital Downgrades Moderna (MRNA) to Sector Perform
-
Moderna (MRNA) PT Lowered to $157 at Piper Sandler
-
Moderna (MRNA) PT Lowered to $120 at Jefferies
-
Midday movers: Meta Platforms, Lilly rise; Arm, Moderna fall
-
Moderna stock plunges as guidance cut on low EU sales, U.S. vaccine competition
-
Moderna (MRNA) Tops Q2 EPS by 2c; cuts revenue guidance
-
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Stocks expected to have increasing option volume: MRNA HSY RBLX K LH WEN SHAK RDDT
-
Moderna (MRNA) August weekly option IV elevated into quarter results
-
Moderna (MRNA) August 2 weekly 120 straddle priced into quarter results
-
GSK (GSK) and Flagship Pioneering partner to discover novel medicines and vaccines
-
Moderna (MRNA) Appoints David Rubenstein to its Board
-
Moderna (MRNA) Announces Resignations of Robert Langer and Stephen Berenson from Board
-
David Rubenstein Joins Moderna's Board of Directors
-
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
-
Moderna (MRNA) Partners with Mitsubishi Tanabe Pharma to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
-
Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
-
Moderna (MRNA) option IV flat into quarter results
-
Moderna (MRNA) Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
-
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
-
US Inks Vaccine Deal With Moderna (MRNA) as Bird Flu Threat Looms - Bloomberg
-
Midday movers: Nike and Accolade fall; Humana and Infinera rise
-
Moderna (MRNA) Reports Positive EMA Opinion Recommending Marketing Authorization of mRESVIA
-
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
-
TD Cowen Reiterates Hold Rating on Moderna (MRNA)
-
Moderna (MRNA) July 5 weekly 116 puts and July 125 puts active amid wide price movement
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
-
Jefferies Reiterates Buy Rating on Moderna (MRNA)
-
Moderna (MRNA) sees heavy early weakness amid CDC presentation
-
Moderna (MRNA) PT Raised to $150 at Argus
-
TD Cowen Reiterates Hold Rating on Moderna (MRNA)
-
Moderna (MRNA) Reports Positive Phase 3 Efficacy Data for mRNA-1283
-
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
-
Moderna (MRNA) price target raised at Oppenheimer after RSV vaccine approval
-
Moderna (MRNA) PT Raised to $179 at Oppenheimer, 'mResvia is competitive as an RSV vaccine'
-
Moderna (MRNA): expects to file for approval of RSV vaccine in adults aged 18 to 59 this year - Company executive at conference
